Recursion Pharmaceuticals (RXRX)
Recursion Pharmaceuticals (NASDAQ: RXRX)
Founded: 2013
Headquarters: Salt Lake City, Utah, USA
Focus Area: Drug discovery using artificial intelligence (AI) and automation
🔬 Key Pipelines / Technologies
| Pipeline | Indication | Clinical Stage | Notes |
|---|---|---|---|
| REC-994 | Cerebral Cavernous Malformations (CCM) | Phase 2 | Positive results announced on Feb 6, 2025 |
| REC-4881 | Familial Adenomatous Polyposis (FAP) | Phase 2 | Ongoing |
| REC-3964 | Bacterial infections | Phase 1 | Ongoing |
| REC-617 | Advanced solid tumors | Phase 1/2 | Positive interim data released in Dec 2024 |
📅 Recent Key Events
| Date | Event |
|---|---|
| 2025.02.06 | REC-994 Phase 2 results announced – positive outcome |
💰 Financial Information
| Item | Value |
|---|---|
| Market Cap | ~$2.685 billion |
| Cash Holdings | ~$428 million |
| Operating Loss (2024) | ~$350 million |
| Number of Employees | ~500 |
| Estimated Cash Runway | ~1.4 years |
Formula = (Current Assets - Current Liabilities) / Previous Year's Operating Loss
Source: 2024 Annual Report Summary
🚀 Upcoming Catalysts / Risk Factors
- Upcoming Milestones:
- H2 2025: REC-4881 Phase 2 results expected
- 2025: Final Phase 1/2 data readout for REC-617
- Risk Factors:
- Potential failure or delay in clinical trials
- Regulatory uncertainty around AI-driven drug discovery
- Increasing competition from other AI-focused biotech companies
This content is provided for informational purposes only and does not constitute investment advice.
Investment decisions are the sole responsibility of the individual, and any gains or losses belong solely to the investor.
Updated: 2025-03-22